Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Orphanet J Rare Dis. 2014 Nov 26;9:169. doi: 10.1186/s13023-014-0169-6.
Orphanet J Rare Dis. 2014.
PMID: 25425121
Free PMC article.
Clinical Trial.
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
Goker-Alpan O, Nedd K, Shankar SP, Lien YH, Weinreb N, Wijatyk A, Chang P, Martin R.
Goker-Alpan O, et al. Among authors: wijatyk a.
JIMD Rep. 2015;23:7-15. doi: 10.1007/8904_2015_422. Epub 2015 Mar 31.
JIMD Rep. 2015.
PMID: 25822820
Free PMC article.
Item in Clipboard
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
Goláň L, Goker-Alpan O, Holida M, Kantola I, Klopotowski M, Kuusisto J, Linhart A, Musial J, Nicholls K, Gonzalez-Rodriguez D, Sharma R, Vujkovac B, Chang P, Wijatyk A.
Goláň L, et al. Among authors: wijatyk a.
Drug Des Devel Ther. 2015 Jul 8;9:3435-44. doi: 10.2147/DDDT.S80928. eCollection 2015.
Drug Des Devel Ther. 2015.
PMID: 26185417
Free PMC article.
Clinical Trial.
Item in Clipboard
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.
Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, Ramaswami U, West M, Wijatyk A, Giugliani R; Fabry Outcome Survey Study Group.
Beck M, et al. Among authors: wijatyk a.
Mol Genet Metab Rep. 2015 Mar 5;3:21-7. doi: 10.1016/j.ymgmr.2015.02.002. eCollection 2015 Jun.
Mol Genet Metab Rep. 2015.
PMID: 26937390
Free PMC article.
Item in Clipboard
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S.
Papanicolaou GA, et al. Among authors: wijatyk a.
Clin Infect Dis. 2019 Apr 8;68(8):1255-1264. doi: 10.1093/cid/ciy706.
Clin Infect Dis. 2019.
PMID: 30329038
Free PMC article.
Clinical Trial.
Item in Clipboard
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
Maertens J, Cordonnier C, Jaksch P, Poiré X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S.
Maertens J, et al. Among authors: wijatyk a.
N Engl J Med. 2019 Sep 19;381(12):1136-1147. doi: 10.1056/NEJMoa1714656.
N Engl J Med. 2019.
PMID: 31532960
Clinical Trial.
Item in Clipboard
Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis.
Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A; CMV Consensus Forum.
Natori Y, et al.
Clin Infect Dis. 2018 Feb 1;66(4):617-631. doi: 10.1093/cid/cix793.
Clin Infect Dis. 2018.
PMID: 29020339
Item in Clipboard
Cite
Cite